AbolerIS Pharma will develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in inflammatory, autoimmune and degenerative diseases. Anti-CD45RC monoclonal antibody to deplete effector T cells and preserve regulatory and memory T cells. IL-34 cytokine to induce tolerogenic macrophages/DCs and regulatory T cells. Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance.